Microsoft tablet computer aimed at taking on IPad – Bloomberg
Microsoft Corp. unveiled its own Windows-powered tablet computer called Surface, altering its strategy of focusing on software and relying on partners to make the machines in a renewed attempt to take on the Apple...
Newark-based iBio makes progress on patent
The U.S. Patent Office has accepted a patent application for the iBio Inc. iBioModulator platform. The platform aims to improve the potency and effectiveness of vaccines used to fight flu, anthrax and other diseases...
AstraZeneca among pharma companies seeking antibiotics answers
A growing worry in medicine is bugs’ increasing resistance to antibiotics. At AstraZeneca’s research centre near Boston, scientists toil to find new weapons. Machines screen thousands of drugs each year, robotic arms nimbly handling...
DuPont opens new office building
DuPont last week opened a new five-story, 220,000 square foot office building at its Chestnut Run facility – incorporating sustainability into the building design and using more than 20 DuPont innovations. The building is...
SDIX reports loss, partnership with drug company
SDIX, a Glasgow, Del. provider of biotechnology-based products and services reported a loss for the quarter and a partnership with a drug company. Revenue for the first quarter of 2012 was $5.6 million, down...
DuPont acquires remainder of soy venture
DuPont, on May 1, took full ownership of St. Louis-based soy-based ingredients joint venture Solae. DuPont previously owned 72 percent of the joint venture while grain merchant Bunge owned the remainder. Published reports indicate...
WEEK IN REVIEW – A tale of 2 pharma companies, casino earnings perk up
Most businesspeople in Delaware know little about Incyte.
The pharmaceutical development company, based in DuPont research space at the Experimental Station has quietly built a portfolio of promising drugs while posting big losses.
Earlier in the...
Incyte posts loss as stock price stays around 52-week high
Drug developer Incyte Corp. is reporting revenue from a new product on the market, although the company's loss widened in the first quarter, due to higher research and other expenses as its pharmaceuticals moved...
AstraZeneca $1.26 paying billion for developer of gout drug
AstraZeneca headquarters in London.
AstraZeneca is betting on the success of a promising drug used to treat gout in its merger deal for Ardea Biosciences, Inc. AstraZeneca will acquire Ardea, a San Diego-based biotechnology company...
AstraZeneca, Bristol-Myers Squibb drug wins OK from European panel
AstraZeneca and Bristol-Myers Squibb Company reported a committee for a European Union agency has recommended the approval of FORXIGA tablets for the treatment of type 2 diabetes.
The drug is used in additon to diet...